SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL)
IMCL 0.1590.0%Oct 5 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Fox who wrote (1990)2/12/2002 7:45:14 PM
From: Jdaasoc  Read Replies (1) of 2515
 
The Dell exec's wife with pancreatic and ovary cancer that got into treatment program with Erbitux and traditional chemotherapy, which was not part of the failed Phase III FDA trial on colorectal cancer, after donating money a lot of money means nothing in terms of the effectiveness of Erbitux.
Erbitux is a monoclonal antibody against EGF recreptor. The E in EGF stands for Epidermal as in skin. Last time I checked a pancreas and ovaries would not be cells one would associate with a high concentration of EGF receptors on which the monoclonal antibody to acts upon in combination with traditional cancer chemotherapy.

Getting back to IMCL, any guess on the additional cash burn rate beyond their existing $20 M per month for the fast track construction of the $250 M production plant that makes nothing approved by the FDA. I reported last week that I saw dump trucks leaving the construction site at 2 to 3 per minute and an ant trail in both directions on Rt 202 of 30-40 dump trucks. My figure is a faster burn rate of about $40 M per month in total. IMO $10-15 M pr month in construction spending is reasonable and because I keep hearing the word fraud in every news release about IMCL. When lawyers from BMY and shareholders get to court that will add $2-3 M per month in expenses. Somehow I feel the $ 1 B in cash from BMY will disappear before the time it takes to complete a new round of drug trials for Erbitux.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News